1.
J Pediatric Infect Dis Soc
; 12(3): 152-155, 2023 Apr 18.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36928172
RESUMEN
Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.
